Compare State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF (FLRN) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF vs Merck & Co., Inc. — how do they compare? State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF trades at $30.78 (market cap $3.06B), while Merck & Co., Inc. trades at $144.83 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 114.8× State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF's market cap, and Merck & Co., Inc. pays a 2.39% dividend while State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF for 15 Days and Merck & Co., Inc. for 98 Days on average.
| FLRN | MRK | |
|---|---|---|
Market Cap | $3.06B | $351.28B |
Volume | 6,296,473 | 7,969,665 |
Sector | Fixed Income | Health |
52-Week High | $30.86 | $156.43 |
52-Week Low | $30.65 | $82.49 |
Typical Hold Time | 15 Days | 98 Days |
Enterprise Value | — | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLRN (SPDR Bloomberg Investment Grade Floating Rate ETF) trades at $30.75 with minimal daily movement (+0.03%). Technical indicators show a bearish trend with strong selling pressure in moving averages, while oscillators remain neutral. The ETF maintains consistent $0.11 quarterly dividend payments through 2026, providing income stability amid current market volatility.
FLRN offers protection against rising interest rates with near-zero duration exposure, though significant financial sector concentration presents risk. Current market sentiment reflects cautious optimism as institutional investors add positions while technical indicators suggest near-term pressure. The floating rate structure positions FLRN favorably in inflationary environments.
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF
FLRN invests in U.S. dollar-denominated investment-grade floating rate notes with maturities under five years. It provides exposure to corporate and supranational debt whose interest payments adjust with market rates, helping to mitigate interest rate risk.
Read more on FLRN →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
